ArticleOral health & preventive dentistry2021
Peri-implant Sulcular Fluid Galectin-1, Soluble Urokinase Plasminogen Activator Receptor and IL-1β Levels under Peri-implant Inflammatory Conditions.
Article in Oral health & preventive dentistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.
- Diagnostic value of MMP-8, IL-1β and IL-6 in peri-implantitis: a systematic review and meta-analysis.Oral and maxillofacial surgery · 2026Pooled it
- Clinical and Radiographic Status and PISF Levels of PGE2 Around Cement and Screw Retained Implants.International dental journal · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSoluble urokinase plasminogen activator receptor (suPAR) and interleukin 1-beta (IL-1β) are inflammatory biomarkers, whereas galectin-1 is an anti-inflammatory cytokine. The relationship between suPAR, galactin-1 and IL-1β levels in peri-implant sulcular fluid (PISF) in relation to dental implants remains unaddressed. The aim was to assess suPAR, galectin-1, and IL-1β levels in PISF under peri-implant inflammatory conditions. MATERIALS AND
methodsDemographic data and information related to jaw location and duration of implants in function as well as systemic health was retrieved from patients' dental records. Peri-implant plaque and gingival indices (PI and GI, respectively), probing depth (PD) and crestal bone loss (CBL) were recorded. The PISF was collected and levels of suPAR, galectin-1 and IL-1β were determined using standard techniques. Sample-size estimation and statistical analyses were done. Correlation of suPAR and galectin-1 with IL-1β were assessed via logistic regression. p-values < 0.05 were considered statistically significant.
resultsSeventy-two patients (45 males and 27 females) with peri-implant diseases were included. Thirty-six patients (22 males and 14 females) had peri-implant mucositis; 36 (23 males and 13 females) had healthy peri-implant tissues. The PISF volume was statistically significantly higher among patients with (0.52 ± 0.05 µl) than without peri-implant diseases (0.06 ± 0.01 µl) (p < 0.001). The PISF levels of suPAR (p < 0.01), galectin-1 (p < 0.01) and IL-1β (p < 0.01) were statistically significantly higher among patients with than without peri-implant diseases. In patients with peri-implant mucositis, PISF suPAR (p < 0.001) and galectin-1 (p < 0.001) levels correlated with PISF IL-1β levels. In patients with peri-implant mucositis, increasing peri-implant PD and IL-1β levels directly correlated with increased PISF suPAR (p < 0.001) and galectin-1 (p < 0.05) levels.
conclusionIncreased PISF levels of suPAR, galectin and IL-1β suggest that these proteins possibly contribute towards the pathogenesis of peri-implant inflammation, and are potential biomarkers of peri-implant diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.